Plant Name: Dendrobium chrysotoxum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; HTR2C; DRD3; | |
| TSHR; OPRD1; | |
| PTPN1; PTPN2; | |
| GAA; | |
| RECQL; TDP1; CDA; ADK; HSD17B1; | |
| CA2; CA1; CA12; CA9; CA3; CA14; CA7; CA5A; CA4; CA6; | |
| PPARA; PPARD; | |
| NR1H4; | |
| BACE1; | |
| ELANE; | |
| TLR2; | |
| STAT6; | |
| VCP; | |
| SLC28A2; SLC28A3; SLC28A1; | |
| HTT; FABP3; FABP5; FABP2; FABP4; MCL1; MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Endoplasmic reticular retrotranslocon family | VCP | Transitional endoplasmic reticulum ATPase | P55072 | CHEMBL1075145 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.540E-10 | 6.590E-07 | ADORA1, ADORA2A, CYP19A1, ELANE, NR1H4, PPARA, PPARD, PTPN2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.387E-09 | 1.074E-05 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, CDA, NR1H4, PPARA, PPARD, PTPN1 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.445E-07 | 3.457E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 5.331E-07 | 3.628E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 8.885E-07 | 5.229E-04 | ADORA1, ADORA2A, CA2, CA7, DRD3, HTR2C, HTT |
| BP | GO:0008152; metabolic process | GO:0071073; positive regulation of phospholipid biosynthetic process | 1.275E-06 | 6.456E-04 | FABP3, HTR2C, NR1H4 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.275E-06 | 6.456E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0050896; response to stimulus | GO:0010033; response to organic substance | 4.286E-06 | 1.805E-03 | ADORA2A, CA2, CA3, CA9, CYP1B1, DRD3, ELANE, FABP3, FABP4, MCL1, NR1H4, OPRD1, PPARA, PPARD, TLR2, TSHR, VCP |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 4.310E-06 | 1.805E-03 | ADORA2A, CA2, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.043E-06 | 1.893E-03 | CYP19A1, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 6.304E-06 | 2.250E-03 | SLC28A2, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 6.304E-06 | 2.250E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 6.304E-06 | 2.250E-03 | SLC28A2, SLC28A3 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 8.394E-06 | 2.812E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0032501; multicellular organismal process | GO:0045187; regulation of circadian sleep/wake cycle, sleep | 1.445E-05 | 4.559E-03 | ADORA1, ADORA2A, DRD3 |
| BP | GO:0065007; biological regulation | GO:0035813; regulation of renal sodium excretion | 1.697E-05 | 5.203E-03 | ADORA1, ADORA2A, DRD3 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.888E-05 | 5.340E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.888E-05 | 5.340E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.888E-05 | 5.340E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.888E-05 | 5.340E-03 | ADORA1, ADORA2A |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 2.076E-05 | 5.581E-03 | ADORA2A, MAPT, OPRD1, VCP |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.205E-05 | 5.785E-03 | ADORA2A, CA2, CA7, DRD3, HTT, NR1H4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.345E-05 | 6.079E-03 | ADORA1, ADORA2A, CA2, CA7, DRD3, HTR2C, HTT, NR1H4 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 2.490E-05 | 6.380E-03 | DRD3, FABP3, PPARA, PPARD |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.622E-05 | 6.561E-03 | CYP19A1, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008210; estrogen metabolic process | 2.991E-05 | 7.236E-03 | CYP19A1, CYP1B1, HSD17B1 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 3.770E-05 | 8.552E-03 | PTPN1, PTPN2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.230E-23 | 2.678E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.636E-18 | 1.049E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.786E-16 | 9.723E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.606E-23 | 4.373E-21 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.680E-08 | 6.553E-07 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 4.734E-06 | 1.231E-04 | OPRD1; ADORA2A; ADORA3; ADORA1; HTR2C; DRD3; TSHR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.224E-05 | 2.386E-04 | HSD17B1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.498E-04 | 3.897E-03 | HSD17B1; CYP1B1; CYP19A1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.497E-04 | 4.545E-03 | FABP4; ADORA1; TSHR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.420E-03 | 1.123E-02 | ADORA2A; ADORA1; PPARA; TSHR |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.026E-04 | 7.829E-03 | CA2; NR1H4; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.068E-03 | 1.042E-02 | CYP1B1; CYP3A4; CYP2C19 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.174E-03 | 2.063E-02 | OPRD1; ADORA3; ADORA1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 6.831E-03 | 3.806E-02 | STAT6; PTPN2; MCL1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 7.952E-03 | 3.919E-02 | OPRD1; ADORA3; ADORA1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.682E-03 | 3.409E-02 | CDA; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.289E-03 | 1.623E-02 | CYP3A4; CYP2C19 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.440E-03 | 1.123E-02 | CA2; CA4 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 8.039E-03 | 3.919E-02 | VCP; TLR2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ELANE; OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | VCP |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| NA: NA | Primary insomnia | NA | HTR2C |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRD1; ADORA2A; ADK; HTR2C |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ELANE; ELANE; ADORA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; HTR2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; HTR2C |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; ADORA1; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; CYP3A4; HTR2C |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA1; CA1; CA1; ADORA2A |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; HTR2C; HTR2C |
| NA: NA | Edema | NA | CA2 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ELANE; ADORA1; ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ELANE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; TLR2 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; HTR2C; HTR2C |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; CA1; CA9; TLR2; MCL1 |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; TLR2; CDA |